Evidence map›Paper›PMID 37291617›Full record

ArticleParasites & vectors2023

Evaluation of renal values during treatment for heartworm disease in 27 client-owned dogs.

C Autumn M Vetter, Alison G Meindl, Bianca N Lourenço, Michael Coyne, Corie Drake, Rachel Murphy, Ira G Roth, Andrew R Moorhead

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

C Autumn M VetterDepartment of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA. cam18@uga.edu.
Alison G MeindlDepartment of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Fort Collins, CO, USA.
Bianca N LourençoDepartment of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Michael CoyneIDEXX Laboratories, Westbrook, ME, USA.
Corie DrakeIDEXX Laboratories, Westbrook, ME, USA.
Rachel MurphyIDEXX Laboratories, Westbrook, ME, USA.
Ira G RothDepartment of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Andrew R MoorheadDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
University of Georgia · USIDEXX Laboratories (United States) · USColorado State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCanine heartworm disease (CHD) caused by Dirofilaria immitis remains a common preventable disease with increasing incidence in some parts of the USA. The treatment guidelines of the American Heartworm Society (AHS) currently recommend monthly macrocyclic lactone administration, 28 days of doxycycline given orally every 12 h and three injections of melarsomine dihydrochloride (1 injection on day 2 of treatment followed 30 days later by 2 injections 24 h apart). Minocycline has also been utilized when doxycycline is unavailable. The systemic effects of CHD, which particularly impact cardiac and renal function, have been described, with infected dogs often experiencing renal damage characterized by an increase in serum concentrations of renal biomarkers. Although the AHS treatment protocol for CHD has been shown to be safe and effective in most cases, the potential for complications remains. No study as of yet has evaluated changes in symmetric dimethylarginine (SDMA), a sensitive marker of renal function, during treatment for CHD. The purpose of the present study was to evaluate renal function in dogs by measuring serum creatinine and SDMA concentrations during the adulticide treatment period.

methodsSerum creatinine and SDMA concentrations were measured in 27 client-owned dogs affected by CHD at the following time points: prior to starting doxycycline or minocycline therapy (baseline), during doxycycline or minocycline therapy (interim), at the time of the first dose of melarsomine (first dose), at the time of the second dose of melarsomine (second dose) and at the dog's follow-up visit after treatment, occurring between 1 and 6 months after completion of therapy (post-treatment). Concentrations of creatinine and SDMA were compared between time points using a mixed effects linear model.

resultsMean SDMA concentrations following the second dose of melarsomine were significantly lower (-1.80 ug/dL, t-test, df = 99.067, t = -2.694, P-Value = 0.00829) than baseline concentrations. There were no other statistically significant differences in the concentration of either biomarker between the baseline and the other time points in CHD dogs undergoing treatment.

conclusionsThe results suggest that the current AHS protocol may not have a substantial impact on renal function.

Indexed as

Dirofilaria immitisDirofilariasisDog DiseasesFilaricidesHeart DiseasesAnimalsArsenicalsBiomarkersCreatinineDogsDoxycyclineMinocyclineTriazinesArsenicalsBiomarkersCreatinineDoxycyclineFilaricidesmelarsomineMinocyclineTriazinesCanineDirofilaria immitisDirofilariasisKidney diseaseMelarsomineSymmetric dimethylarginine

Identifiers

PMID37291617
PMCPMC10251593
OpenAlexW4379791146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.